Key result
CYP2C9 IVS8-109T/T genotype is linked to lower losartan metabolic ratio versus A/A genotype.
Why the study?
The influence of the CYP2C9 IVS8-109A>T polymorphism on losartan metabolic ratio and its frequency in different populations was unclear.
Does the CYP2C9 IVS8-109A>T polymorphism affect losartan hydroxylation in healthy Ecuadorian volunteers?
Observational
Does the CYP2C9 IVS8-109A>T polymorphism affect losartan hydroxylation in healthy Ecuadorian volunteers?
p-value: p=<0.05
The CYP2C9 IVS8-109T allele is associated with increased losartan hydroxylation capacity in healthy Ecuadorians, though it is less frequent than in Swedish or Asian populations.
Extends CYP2C9 data to Ecuadorians; leaves open clinical translation for losartan dosing.
AIM: The CYP2C9 IVS8-109T allele was recently found to be more frequent among Swedish individuals, who have the highest losartan metabolic ratio (MR; losartan:E-3174). Thus, the influence of the CYP2C9 IVS8-109A>T polymorphism on the losartan MR was evaluated among healthy Ecuadorians. In addition, the frequency of the CYP2C9 IVS8-109A>T polymorphism was determined. RESULTS: Among CYP2C9-homozygous wild-types, those with the CYP2C9 IVS8-109T/T versus A/A genotypes had a lower MR (p < 0.05). Furthermore, the frequency of the CYP2C9 IVS8-109T variant was lower in Ecuadorians (21.4%; p < 0.001) than in populations from Sweden or Asia (ranging from 32 to 46%). CONCLUSION: In this Ecuadorian population, the CYP2C9 IVS8-109T allele was associated with an increased CYP2C9 hydroxylation capacity. Further investigation needs to be carried out in order to clarify the relevance of the SNP of CYP2C9 IVS8-109A>T on losartan hydroxylation across populations and its potential implications in CYP2C9 activity.
No takes yet. Share an insight, caveat, or question.
Dorado et al. (2014) conducted an observational in Healthy volunteers. CYP2C9 IVS8-109T/T genotype vs. CYP2C9 IVS8-109A/A genotype was evaluated on Losartan metabolic ratio (MR; losartan:E-3174) (p=<0.05). The CYP2C9 IVS8-109T/T genotype was associated with a lower losartan metabolic ratio compared to the A/A genotype among healthy Ecuadorians (p < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: